Staar Surgical (NSDQ:STAA) won regulatory approval from India’s Central Drugs Standard Control Organization for its LASIK eye surgery alternative, the Visian implantable collamer lens with CentraFlow.
STAAR Surgical Co
Sitting pretty: Even in recession-ravaged countries in Southern Europe, beauty sells | Earnings Roundup
Despite a crippling recession which puts it in the epicenter of the European debt crisis, it still seems Southern Europe puts a premium on not just the beauty of its land, but those of its people as well.
On Wednesday Allergan (NYSE:AGN) reported stronger than expected sales of its breast implants, Botox and other aesthetic devices in places like Spain, where the unemployment rate tips 24% – more than 3 times that of the U.S.
Teleflex taps former Tomotherapy CFO Powell as finance chief | Personnel Roundup
Teleflex (NYSE:TFX) named Thomas Powell CFO effective March 9, replacing Richard Meier, who was ousted the same day.
Powell joined the Limerick, Pa.-based device maker last year as senior vice president of global finance, according to regulatory filings, prior to which he was CFO of TomoTherapy, which was subsequently sold to Accuray (NSDQ:ARAY).
AGFA Gevaert slides to Q4, 2011 red | Earnings Roundup
AGFA Gevaert slides to Q4, 2011 red
AGFA Gevaert (EBR:AGFB) swung to red ink for the 4th quarter and 2011.
BSX offers 10 year warranties on newly cleared defibrillators | Regulatory Roundup
Boston Scientific Corp. (NYSE:BSX) landed FDA clearance for its Incepta, Energen and Punctua cardiac implants to treat heart failure and sudden cardiac death.
To go along with the new defibrillator systems, the Natick, Mass.-based med-tech titan is providing an extended warranty for the Incepta and Energen family of defibrillators.
Diabetes: Medtronic wins clearance for next-gen clinical continuous glucose monitor | Regulatory Roundup
Medtronic Inc. (NYSE:MDT) won FDA clearance for its next generation iPro2 Professional continuous glucose monitor.
The iPro2 Professional is a clinician-owned device that collects glucose data from a sensor inserted into a patient’s skin.
The device tracks the patient’s glucose levels for 3 days, collecting data as many as 288 times each day. The information may provide insight into how diet, medication and daily activities affect a patient’s glucose levels.
Staar Surgical lands European approval for NanoFLEX | Regulatory Roundup
Staar Surgical Co. (NASDAQ:STAA) landed CE Mark approval in the European Union for its nanoFLEX Toric IOL for use in cataract patients with astigmatism.
First shipments of the nanoFLEX intraocular lens are scheduled to roll out to the European market in the first quarter of 2012.
STAAR Surgical Receives Approval to Market its Toric Collamer IOL in Europe
Allows Company to Expand its Presence in the Premium IOL Market in Europe
with the nanoFLEX™ Toric IOL
First Shipments Scheduled for Q1 2012
MONROVIA, CA, November 16, 2011 — STAAR Surgical Company (NASDAQ: STAA),
a leading developer, manufacturer and marketer of minimally invasive ophthalmic products,
today announced it has received CE Mark approval for its nanoFLEX™ Toric Collamer® Single
Piece IOL. The CE Mark approval of the nanoFLEX Toric IOL will allow the Company to
expand its product offerings in the European Union (EU) to include an improved solution for
cataract patients with astigmatism. The nanoFLEX Toric IOL was approved for correction of
1.0 diopters to 4.0 diopters of cylinder in 0.5 diopter steps. The Company received CE Mark
Masimo plunges after missing Q3 earnings target | Earnings Roundup
Shares of Masimo Corp. (NSDQ:MASI) plunged more than 12 percent today after the patient monitoring device maker missed third-quarter earnings expectations and lowered its sales and earnings guidance for the rest of 2011.
MASI shares were trading at $19.61 as of about 1 p.m. today, down 12.1 percent.
Diabetes: Remote monitoring diabetes management system wins FDA clearance | Regulatory Roundup
ALR Technologies Inc. (OTC:ALRT) landed FDA clearance for its Health-e-Connect System for diabetes management programs.
The web-based patient management platform allows doctors to remote monitor diabetic patients, a system that could result in significant savings to the the U.S. health care system through enhanced adherence to care plans, according to ALRT.
Allergan beats and raises on 14 percent boost in sales | Earnings Roundup
Allergan Inc. (NYSE:AGN) touted a strong quarter on the back on growing sales.
The Irvine, Calif.-based company saw strong growth in revenue in the three months ended June 30, posting $1.4 billion in sales, which amounts to a 14 percent increase over $1.2 billion in sales reporting during the same time last year.
Device sales jumped 12 percent to $245 million for the quarter, compared to $219 million in Q2 2010.